Abstract: A lookup table is fixed in electronically readable hardware such as a ROM inside of an integrated circuit responsible for controlling or interfacing with a USB bus. An index is read and used to pick an entry in the lookup table. That entry provides a Product ID that is combined with fixed vendor information to complete the identification information provided for in the USB specification.

Abstract: The present invention discloses a method and apparatus for computing CRC codes for fixed length page buffers of user data where the user data arrives from a transmission device in variable length packets with the packet contents being out of sequential order. The received data is written to a storage device after being restored to the correct sequential order. The data packets are comprised of a header portion and a data portion. The transmission and compression methods commonly employed by the transmission device dictates that the header portion of each packet follows the data portion. The present invention computes a complete CRC code for the data stored in a page buffer in real time as the packets are received by using several registers for saving intermediate CRC codes and circuitry to combine partial CRC codes for those packet portions received out of order.

Abstract: Compounds of the formula ##STR1## are disclosed, wherein R.sub.1, represents secondary alkyl; aralkyl; cycloalkyl; heteroaryl substituted alkyl; norbornyl; and substituted secondary alkyl, aralkyl, cycloalkyl, heteroaryl substituted alkyl, norbornyl; and para-substituted phenyl groups; and R.sub.2 and R.sub.3 are hydrogen or pharmacologically acceptable acyl groups. The compounds of the invention are useful as cardiovascular vasodilator or anti-hypertensive agents. The therapeutically useful compounds of the invention as well as similar 5'-N and N-6 substituted adenosine 5'-uronamides are prepared, in accordance with a novel process, from isopropylidene (or otherwise suitably blocked) inosine-5' -uronic acid. Isopropylideneinosine-5' -uronic acid is reacted with a suitable inorganic acid halide, such as thionyl chloride, to yield 6-halogeno-9-[ 2',3' -O-isopropylidene-.beta.-D-ribofuranosyl-5-uronic acid halide] -9H-purine. This intermediate is reacted with an amine of the general formula R.sub.4,R.sub.

Abstract: The present invention discloses a compound of the formula: ##STR1## where R.sub.1 is hydrogen or the group ##STR2## where R.sub.3 and R.sub.4 are the same or different and are hydrogen, C.sub.1 to C.sub.12 linear or branched alkyl, C.sub.3 to C.sub.7 cycloalkyl, C.sub.6 to C.sub.10 aryl unsubstituted or substituted with C.sub.1 to C.sub.6 linear or branched alkyl, C.sub.1 to C.sub.6 linear or branched alkoxy, nitro, amino, amino substituted with at least one C.sub.1 to C.sub.6 linear or branched alkyl or phenyl, C.sub.2 to C.sub.10 aralkyl, C.sub.4 to C.sub.8 heteroaryl wherein said heteroatom is nitrogen, phosphorous, sulfur or oxygen, and R.sub.2 is hydrogen, or taken together with R.sub.5, forms a chemical bond, and R is a monosaccharide radical selected from the group consisting essentially of glucose, fructose, ribose, 2-deoxyribose, mannose, galactose, xylose and arabinose.

Abstract: Compounds are disclosed having the formulae: ##STR1## wherein R.sub.1 is selected from the group, consisting of radicals represented by the general formulae: ##STR2## wherein Y is selected from the group consisting of lower alkyl, lower alkoxy, and halogen; Z is oxygen, sulfur or --NH, Q is --CH or nitrogen; a is zero or an integer of from one to three; andwherein, R.sub.2 is selected from the group consisting of hydrogen and straight chain, branched and cyclic hydrocarbyl radicals having from one to four carbon atoms, and optionally substituted with a hydroxyl radical; andwherein X is two hydrogen atoms or oxygen and B is selected from oxygen and nitrogen, and pharmaceutically acceptable salts thereof, with the proviso that when X is two hydrogen atoms, B is oxygen, and with the further proviso that when B is oxygen then R.sub.1 cannot be a phenyl or a substituted phenyl radical. Pharmaceutical preparations using these compounds and a method for inducing an adenosine response mediated by the adenosine A.sub.

Abstract: New, N-6 monosubstituted adenosine derivatives are disclosed which have significant cardiac vasodilatory effect. The compounds of the invention include 6-(cyclo-butyl amino)-9-(.beta.-D-ribofuranosyl)-9H-purine, 6-(2-methyl-2-phenyl hydrazino)-9-(.beta.-D-ribofuranosyl)-9H-purine, and compounds of the general formula: ##STR1## wherein R.sub.1 is H, lower alkyl, lower alkoxy, alkylamino, or arylamino, R.sub.2 is H, lower alkyl, hydroxymethyl, phenyl or substituted phenyl, R.sub.3 is H, lower alkyl, phenyl, substituted phenyl, R.sub.3 is H, lower alkyl, phenyl, substituted phenyl, 2 or 3-thienyl, or 2 or 3-pyridyl, R.sub.4 is H or lower alkyl, and R.sub.5 is H or lower acyl. Particularly active as a cardiac vasodilator is the compound (-)-6-(R-1-phenyl-2-butyl amino)-9-(.beta.-D-ribofuranosyl)-9H-purine.

Abstract: Compounds of the formula are disclosed, wherein R1, represents secondary alkyl; aralkyl; cycloalkyl; heteroaryl substituted alkyl; norbornyl; and substituted secondary alkyl, aralkyl, cycloalkyl, heteroaryl substituted alkyl, norbornyl; and para-substituted phenyl groups; and R2 and R3 are hydrogen or pharmacologically acceptable acyl groups. The compounds of the invention are useful as cardiovascular vasodilator or anti-hypertensive agents. The therapeutically useful compounds of the invention as well as similar 5-N and N-6 substituted adenosine 5-uronamides are prepared, in accordance with a novel process, from isopropylidene (or otherwise suitably blocked) inosine-5′-uronic acid. Isopropylideneinosine-5′-uronic acid is reacted with a suitable inorganic acid halide, such as thionyl chloride, to yield 6-halogeno-9-[2′,3′-O-isopropylidene-&bgr;-D-ribofuranosyl-5-uronic acid halide]-9H-purine.

Abstract: Compounds are disclosed having the formulae: ##STR1## .Iadd.wherein R' is hydrogen, lower alkyl or lower alkoxy; r is 0 or 1 and p is zero to four; and .Iaddend.wherein R.sub.1 is selected from the group, consisting of radicals represented by the general formulae: ##STR2## wherein Y is selected from the group consisting of lower alkyl, lower alkoxy, and halogen; Z is oxygen, sulfur or --NH, Q is --CH or nitrogen; a is zero or an integer of from one to three; andwherein, R.sub.2 is selected from the group consisting of hydrogen and straight chain, branched and cyclic hydrocarbyl radicals having from one to four carbon atoms, and optionally substituted with a hydroxyl radical; andwherein X is two hydrogen atoms or oxygen and B is selected from oxygen and nitrogen, and pharmaceutically acceptable salts thereof, with the proviso that when X is two hydrogen atoms, B is oxygen, and with the further proviso that when B is oxygen then R.sub.1 cannot be a phenyl or a substituted phenyl radical.